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Interferon regulatory factor 5 (IRF5) is widely recognized as a risk locus for systemic lupus 
erythematosus (SLE). Risk gene and IRF5 activation is triggered through toll-like receptor 
signaling. In myeloid cells, this leads to production of type I interferon and inflammatory 
cytokines, with enhanced production in cells of individuals harboring IRF5 risk alleles. 
Mouse models have also demonstrated the importance of IRF5 in B cell function, partic-
ularly plasma cell differentiation and isotype switching. Here, we evaluated the major SLE 
risk haplotype of IRF5 on the functional attributes of freshly isolated B cells from human 
subjects who do not have evidence of SLE or other forms of autoimmunity. We took 
this approach to avoid the complications of studying genotype-phenotype relationships 
in B cells that have been chronically exposed to an inflammatory disease environment 
before isolation. We focused on B cell endophenotypes that included gene expression, 
antibody secretion, class switching, and apoptotic susceptibility. We performed IRF5 
overexpression studies, genetic reporter assays and electro-mobility shift assays on 
B and myeloid cell lines. Somewhat surprisingly, the results of our analyses indicate that 
IRF5 risk genotypes do not have a B cell intrinsic effect on these B cell functions. By con-
trast, we confirmed that the IRF5 risk and non-risk haplotypes exert differential effects 
in myeloid cells, including an increased susceptibility to apoptosis conferred by the risk 
haplotype. We also demonstrated an increased binding of the transcription factor spec-
ificity protein 1 to an insertion/deletion present in the risk haplotype. Our findings raise 
the specter that genetic risk alleles can have complex and unexpected lineage-specific 
effects, and these must be carefully considered when guiding or developing therapies 
based on understanding disease risk haplotypes.
Keywords: genetics, B lymphocytes, monocytes, haplotypes, autoimmunity, lupus
inTrODUcTiOn
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by a breach in B cell toler-
ance to self-antigens. Genetic, hormonal, and environmental factors contribute to suscepti bility to 
SLE. The transcription factor interferon regulatory factor 5 (IRF5) is one of approximately 100 genes 
with SLE-associated risk variants (1, 2). Within the immune system, IRF5 is expressed in myeloid cells 
and lymphocytes (3–5). IRF5 has diverse roles in myeloid cells including production of interferon-α 
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(IFNα) and other proinflammatory cytokines (6), regulation of 
the cell cycle and apoptosis (7), macrophage polarization (3), and 
metabolism (8). IRF5 can be activated by toll-like receptor (TLR) 
agonists, including nucleic acid-containing immune complexes 
present in SLE. IFNα can contribute to B cell autoreactivity seen 
in SLE. Many SLE patients have elevated levels of serum IFNα 
and markedly increased expression of interferon-inducible genes 
(9–12). Prior studies have shown that SLE-associated risk alleles 
of IRF5 display increased expression in myeloid cells and influ-
ence monocyte and macrophage activation (8, 13, 14).
IRF5 has direct effects on B cells as well. IRF5 has been shown 
to be critical for terminal B  cell differentiation to plasma cells 
in mice (15, 16). IRF5 also plays a role in isotype switching to 
IgG. Irf5−/− mice have increased levels of IgG1 and decreased 
levels of IgG2c (17). IRF5 has been shown to directly regulate 
transcription of the γ2a locus; Irf5−/− mice do not produce IgG2a 
antibodies (18). There is evidence that IRF5 is necessary for SLE 
development based on studies of pristane-treated C57BL6 Irf5−/− 
and MRL/lpr Irf5−/−mice. The former lack antinuclear antibody 
(ANA) titers and glomerular deposits of immune complexes after 
pristane challenge (18). The latter survive longer, exhibit milder 
glomerulonephritis and lower ANA titers (16, 19) than IRF5 suf-
ficient MRL/lpr mice. Consistent with a contribution of IRF5 to 
autoimmunity, and a contribution of lupus-like inflammation to 
IRF5 expression, the autoimmune C57BL/6.Nba2, NZB/W, and 
Sle123 mouse strains all exhibit increased expression of IRF5 in 
splenic cells compared with C57BL/6 mice (20).
FcγRIIb is known to protect against autoantibody production 
(21, 22). When bound to IgG immune complexes and co-ligated 
to the BCR, FcγRIIb initiates an inhibitory signaling cascade, 
mediated through its immunoreceptor tyrosine-based inhibitory 
(ITIM) motif (22, 23). In mice, a reciprocal regulation of IRF5 and 
FcγRIIb has been reported (20). FcγRIIb is important for B cell 
tolerance by setting a cellular activation threshold. C57BL6.Nba2 
mice develop a lupus-like phenotype due to the presence of the 
Nba2 locus (24). C57BL6.Nba2 Irf5−/− mice exhibit increased 
expression of FcγRIIb and C57BL6 Fcgr2b−/− mice exhibit 
increased expression of IRF5 (20), suggesting reciprocal regula-
tion of IRF5 and FcγRIIb.
Located on chromosome 7 in humans, IRF5 has a total 
of 12  exons. Exons 2–8 and part of 9 are coding. Exon 1 is 
subdivided into four non-coding exons 1a–1d (25). Each non-
coding exon corresponds to a different promoter (26), allowing 
alternative splicing of the gene. There are over 100 known poly-
morphisms of IRF5, but only four are thought to be functional 
(27). Three of these polymorphisms are located in non-coding 
regions of IRF5. The non-coding polymorphisms rs142738614, 
rs2004640, and rs10954213, are located between exons 1d and 
1a, in exon 1b, and in the polyA tail of exon 9, respectively. The 
three alleles have been reported to be in linkage disequilibrium 
(LD) (13). The fourth polymorphism is a 30 bp insertion/dele-
tion (indel) located in exon 6, and inherited independently of 
the three SNPs.
The “T” risk allele of SNP rs2004640 is located in exon 1b 
and introduces a donor RNA splice site, enabling expression 
of mRNAs containing exon 1b (2). Exon 1b transcripts are 
not translated into protein (28) and are expressed at very low 
levels compared with exon 1a transcripts (29), so the functional 
significance of rs2004640 is not entirely clear. The “A” risk allele 
of the SNP rs10954213 in the 3′ UTR of exon 9 introduces a 
more proximal polyA site. This allele has been shown to confer 
increased expression as well as greater mRNA stability likely 
due to decreased susceptibility to degradation of the shorter 
transcripts (30, 31). The polymorphism rs142738614 is an indel 
located 64 bp upstream of exon 1a that refers to the number of 
copies of the 5 bp sequence CGGGG; the risk allele has four copies 
which introduces an additional binding site for the transcription 
factor specificity protein 1 (SP1) (26, 32). To date, the functional 
impact of this additional SP1 binding site in predisposition to 
SLE is unknown.
Currently, data available on the effects of IRF5 risk alleles in 
human B cells are rather limited. In contrast to previous reports, 
using cell lines or B cells of SLE patients (2, 33), we demonstrate 
that in healthy donors, the IRF5 risk and non-risk haplotypes are 
not differentially expressed in B cells in the resting state or after 
TLR activation. In addition, IRF5 haplotypes do not differentially 
regulate B cell differentiation to antibody-secreting cells (ASCs) 
or IRF5-mediated apoptosis, and that IRF5 does not regulate 
FcγRIIb expression in human B cells. Our findings confirm that 
these same IRF5 risk haplotypes do exert differential effects in 
myeloid cells and demonstrate that the 4× CGGGG indel is a 
potential causal allele in this context. Thus, we conclude that 
IRF5 acts indirectly on B cells through B cell extrinsic pathways. 
These data underscore the importance of examining multiple 
cell types when studying risk haplotypes in complex diseases. 
Moreover, they clearly demonstrate that the observation that a 
gene is important in the function of a particular cell type (e.g., the 
importance of IR5 in B cell function) does not necessarily imply 
that disease-associated haplotypes will display differential effects 
intrinsic to that cell type.
MaTerials anD MeThODs
study subjects and study approval
Study participants came from the Genotype and Phenotype 
Registry (GAP) registry at the Feinstein Institute. Their ancestry 
was European (EUR), African (AFR), Hispanic/Latino, South 
Asian (SAS), West Asian, or any combination of these. Subjects 
included premenopausal females and age-matched males, from 18 
to 50 years of age. All subjects included in the study were homozy-
gous risk or homozygous non-risk for IRF5, without autoimmune 
disease and not on corticosteroids, chemotherapeutic or cytotoxic 
drugs, or selective cell depletion therapies, thereby allowing us to 
study effects of the risk haplotype independent of the effects of dis-
ease or medications. The study was approved by the Institutional 
Review Board at the Feinstein Institute for Medical Research. Prior 
written consent was received from all study participants.
irF5 haplotype assembly
Phase 3 genetic data for the IRF5 locus on chromosome 7 were 
extracted from the 1000 Genomes Project browser1 for the 
1 www.internationalgenome.org (Accessed: July, 2017).
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 following populations: AFR, African; AMR, American/Hispanic/
Latino; EAS, East Asian; EUR, European; SAS, South Asian. 
Haplotype maps were constructed for each population using 
Haploview software. Genotyping for representative variants (see 
Genotyping) was performed on subjects in the GAP.2
genotyping
We confirmed the LD of rs142738614, rs2004640, and rs10954213 
by selecting subjects from the GAP Registry that had been 
genotyped for rs2004640 and rs10954213 on the ImmunoChip 
(Illumina). The subjects we selected to further genotype for 
rs142738614 were homozygous for rs10954213. Genotyping for 
rs2004640 and rs10954213 was performed on the ImmunoChip 
by the Center for Genomics and Human Genetics at the Feinstein 
Institute. For rs142738614 genotyping, genomic DNA was 
obtained from 700 subjects homozygous for rs10954213 with 
membership in the GAP registry. The genotyping PCR was per-
formed using the AmpliTaq Gold® DNA Polymerase with Buffer 
II and MgCl2 kit (ThermoFisher Scientific), dNTPs (Takara), 
DMSO (Sigma), and PCR-grade H2O. Primers used for genotyp-
ing were as follows: forward 5′ CTGCAGTTGCCAGGTCAGT 
3′, reverse 5′ CGGACGCAGAGAGGAGAG 3′. Final concentra-
tions of Taq, dNTPS, DMSO, MgCl2, primers, and DNA were 
0.05 U/μl, 0.2 mM, 5%, 1 mM, 0.1 µM, and 0.8 ng/µl, respectively. 
The touchdown PCR utilized the following cycling parameters: 
95°C for 10 min, 12 cycles of: 94°C for 30 s, 62°C for 30 s (0.5°C 
decrease/cycle), 72°C for 1 min, followed by 30 cycles of 94°C for 
30 s, 56°C for 30 s, 72°C for 1 min, followed by 1 cycle of 72°C 
for 5 min. After the PCR, products were subjected to treatment 
with ExoSAP-IT® (Affymetrix) according to the manufacturer’s 
instructions. PCR products were then sent to GENEWIZ (South 
Plainfield, NJ, USA) for sequencing.
human Peripheral Blood Peripheral Blood 
Mononuclear cell (PBMc) and B cell 
isolation
Up to 50  ml of peripheral blood was drawn from consenting 
subjects in the GAP Registry at the Feinstein Institute for Medical 
Research. Blood was collected in heparinized tubes and diluted 
1:1 with Hank’s Balanced Salt Solution (HBSS). Diluted blood 
was overlaid onto Ficoll-Paque PLUS density gradient media (GE 
Healthcare) and centrifuged at 400 × g for 30 min at 25°C with 
the brake and acceleration turned off. The buffy coat layer was 
isolated, washed with HBSS, and resuspended in staining buffer 
[HBSS + 2% heat inactivated fetal bovine serum (FBS) + 1 mM 
EDTA]. PBMCs were counted and used for further experiments 
or when necessary, B  cell isolation was performed with the 
EasySep Human B Cell Enrichment Kit (Stemcell Technologies) 
or the EasySep Human Naïve B Cell Enrichment Kit according to 
the manufacturer’s instructions.
cell lines and Primary cell culture
Ramos (ATCC® CRL-1596™), Raji (ATCC® CCL-86™), Daudi 
(ATCC® CCL-213™), Jurkat (ATCC® TIB-152™), and THP-1 
2 www.GAPRegistry.org (Accessed: August, 2013).
(ATCC® TIB-202™) cells were obtained through the American 
Type Culture Collection and cultured according to ATCC 
recommendations in RPMI supplemented with 10% FBS and 
1% penicillin/streptomycin (ThermoFisher Scientific). Primary 
B cells and PBMCs were cultured in RPMI supplemented with 
10% FBS and 1% penicillin/streptomycin.
Treatment of B cells With irF5-activating 
agents
Primary B cells were seeded into 96-well plates in culture medium 
with final concentrations of 2.5 µM CpG ODN 2006 (Invivogen), 
5 µg/ml R848 (Resiquimod, Invivogen), or medium alone. Cells 
were incubated at 37°C in a humidified 5% CO2 incubator until 
further analysis.
rna isolation and cDna synthesis
Freshly sorted or treated B cells were pelleted and stored in Trizol 
at −80°C until RNA isolation. RNA isolation was performed with 
the Direct-Zol RNA Miniprep or Microprep Kit (Zymo Research) 
according to the manufacturer’s instructions. Freshly isolated 
RNA was reverse transcribed into cDNA using the iScript cDNA 
Synthesis Kit (BioRad) according to the manufacturer’s instruc-
tions and stored at −20°C.
Quantitative real-Time Pcr
All TaqMan assays were obtained from ThermoFisher Scientific. In 
all experiments, mRNA levels were normalized to levels of the endo-
genous control HPRT1 (Hs99999909_m1). TaqMan assays used 
included IRF5 (Hs00158114_m1), FCGR2B (Hs01634996_s1), 
SP1 (Hs00916521_m1), and CD86 (Hs01567026_m1). For IRF5 
expression in sorted B cell subsets and monocytes, cDNA was 
first subjected to preamplification for HPRT1 and IRF5 using 
the TaqMan® PreAmp Master Mix Kit (ThermoFisher Scientific) 
according to the manufacturer’s instructions. All qPCR reactions 
were set up in 384-well format with master mix consisting of 
LightCycler 480 Probes Master (Roche), TaqMan assay, and 
sterile PCR-grade H2O, with 1 µl cDNA per reaction well (5 µl 
cDNA for PreAmp samples). Reactions were performed in 
duplicate. All TaqMan assays were done on a Roche LightCycler 
480 using the following cycling parameters: one cycle of 95°C for 
10 min, and 45 cycles of 95°C for 20 s followed by 60°C for 40 s. 
Analysis of sterile transcripts was done using LightCycler 480 
SYBR Green I Master (Roche), sterile PCR-grade H2O, and 1 µl 
cDNA per reaction well, in duplicate. SYBR Green assays were 
done on a Roche LightCycler 480 using the following cycling 
parameters as reported previously (34): one cycle of 95°C for 
10 min, and 40 cycles of 94°C for 1 min, 58°C for 1 min, and 
72°C for 1  min. A melting curve analysis was also performed 
with continuous acquisition starting at 97°C and ending at 
40°C. Primer sets for sterile transcripts included HPRT1: for-
ward 5′ TGCAGACTTTGCTTTCCTTGGTCAGG 3, reverse 
5′ CCAACACTTCGTGGGGTCCTTTTCA 3′, and germline 
IgG: forward 5′ TCCTCTCAGCCAGGACCAA 3, reverse 5′ 
TCTTGGCATTATGCACCTCC 3′ (34). The final concentration 
of primers used was 0.1 µM. For baseline expression experiments, 
relative mRNA expression levels were calculated using the ΔCt 
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method, 2(Ct endogenous control − Ct gene of interest). For experiments involving 
treatment of B cells with IRF5 activating agents, relative mRNA 
expression levels were calculated using the ΔΔCt method, 
2((Ct gene of interest, untreated − Ct endogenous control, untreated) −  (Ct gene of interest, treated − Ct 
endogenous control, treated)).
Fluorescence-activated cell sorting
For B cell subset sorting, cryopreserved PBMCs were thawed and 
stained with the following monoclonal antibodies for 30 min on 
ice  in the dark: αIgD-FITC, αCD27-PE, αCD38-PE-Texas Red 
(BD  Biosciences), αCD10-PE-Cy7, αCD19-APC (BioLegend), 
and αCD14-Pacific Blue (BD Biosciences). For sorting of 
transfected Raji and Daudi B  cells, cells were transfected 
with either empty or IRF5 overexpressing vectors with a cyan 
fluorescent protein (CFP) overexpressing reporter vector (see 
Transient Transfection and IRF5 Overexpression), and 24 h later 
prepared for sorting by pelleting and resuspended in staining 
buffer. Immediately before sorting, 1  µl propidium iodide (PI) 
(ThermoFisher Scientific) was added to the cells. PI negative, 
CFP-positive cells were sorted, pelleted, and stored in Trizol at 
−80°C. In all experiments, cells were sorted using a BD FACSAria 
or BD FACSAria SORP.
Flow cytometry
The monoclonal antibody 2B6 that was used for FcγRIIb stain-
ing has been described previously (35). All cell surface staining 
conditions took place in staining buffer for 30 min on ice in the 
dark. For baseline FcγRIIb expression in B  cell subsets, cryo-
preserved PBMCs from genotyped GAP subjects were thawed 
and incubated with the following monoclonal antibody cock-
tail: αFcγRIIb-AF488 (Macrogenics), αIgD-PE, αCD27-APC, 
αCD19-PerCP, αCD38-APC-Cy7, αCD10-PE-Cy7 (BioLegend), 
αCD14-Pacific Blue (BD Biosciences), and as a dump gate αCD3 
and αCD16, both AF700 conjugated. The fixable viability dye 
eFluor506 was included for live/dead discrimination (eBiosci-
ence). For analysis of stimulated primary B  cells, cells were 
incubated with eFluor660 fixable viability dye, αCD19-BV421 
(BioLegend) and αFcγRIIb-AF488. For measurement of FcγRIIb 
in IRF5 overexpression experiments, cells were incubated with 
the fixable viability dye eFluor660 and αFcγRIIb-AF488. Only 
CFP+ cells were considered in the analysis. For analysis of 
antibody-secreting cultured B cells, on the fourth day of culture 
B cells were stained with αCD19-APC-Cy7, αCD27-PE, αCD38-
PE-Texas Red, αCD86-BV711 (BioLegend), αCD138-BV421 
(BioLegend), αIgM-PerCP-Cy5.5 (BioLegend), and αIgG-PeCy7 
(BD Biosciences), and viability dye eFluor506. All experimental 
data were acquired on a BD LSRII or LSR Fortessa and analyzed 
using FlowJo software (Treestar).
apoptosis assay
Peripheral blood mononuclear cells or were cultured medium 
with either vehicle (DMSO) or CPT-11 (Sigma) at concentra-
tions of 50 µM. Cells were incubated for 8 h in a 37°C humidified 
5% CO2 incubator. After incubation, cells were stained with 
eFluor506 viability dye, αCD19-APC (BioLegend), and αCD14-
Pacific Blue. Cells were then prepared for analysis using the PE 
anti-active caspase 3 apoptosis kit (BD Biosciences) according to 
the manufacturer’s instructions. Cells were analyzed on a BD LSR 
Fortessa.
elispot assay
On the fourth day of primary B cell culture, Immunolon® flat-
bottom 96-well microtiter plates (ThermoFisher Scientific) were 
coated with goat antihuman IgM (Southern Biotech) at a final 
concentration of 10 µg/ml in HBSS for 1 h at 37°C. Plates were 
then washed and blocked with culture medium for 1 h at room 
temperature. Live cells were counted via trypan blue exclusion 
and seeded as serial 1:2 dilutions in fresh culture medium in the 
plate in duplicate. Plates were briefly spun to settle cells to the 
bottom and incubated overnight in a 37°C humidified 5% CO2 
incubator. Plates were subsequently washed and biotinylated goat 
antihuman IgM was added at a final concentration of 1.6 µg/ml. 
The plates were incubated for 2  h at 37°C. Plates were washed 
again and alkaline phosphatase (AP)-conjugated streptavidin was 
added at a dilution of 1:1,000 and incubated for 1 h at 37°C. Plates 
were washed and developing solution was added: 1 mg/ml BCIP 
(Sigma) in AMP buffer. Color development took place at room 
temperature in the dark until spots appeared; plates were then 
rinsed with dH2O, dried and counted under a light microscope.
elisa
The protocol followed for the ELISA was the same as the ELISpot 
assay with a few modifications. Costar® 96-well flat-bottom 
plates were used (Corning) and blocking was done with 3% FBS. 
IgM standards and sample supernatants were also diluted in 3% 
FBS and incubated for 1.5 h. The incubation with the secondary 
antibody, AP-goat anti human IgM (Southern Biotech) was done 
at a dilution of 1:1,000 and lasted for 1 h. The developing solution 
consisted of 0.05 M Na2CO3, 0.001 M MgCl2, and phosphatase 
substrate (Sigma). Absorbance was measured at 405 nm.
generation of irF5- and  
cPF-Overexpressing constructs
We obtained a plasmid expressing both IRF5 (NM_001098629.1) 
and CFP (GenBank: KT878729.1) as a fusion protein 
(Genecopoeia). Both the IRF5 and CFP ORFs were cloned into 
the pmaxCloning™ vector (Lonza) separately. For the cloning 
of CFP, a PCR was done on the donor fusion protein plasmid 
to introduce HindIII and XhoI sites for more straightforward 
cloning. The PCR primers used were as follows: forward 5′ 
GATAAGCTTTCTTGTACA-AAGTGGTTCG 3′, reverse 5′ 
CACACTCGAGGTAAAAGGACAGG 3′. The PCR consisted 
of 50 ng plasmid DNA, reaction buffer, pfuUltra High-Fidelity 
DNA polymerase, dNTP mix, 0.1 µM primers, and PCR-grade 
H2O. The reaction buffer, polymerase, and dNTP mix were 
taken from the QuikChange II Site-Directed Mutagensis Kit 
(Agilent Technologies). Cycling parameters were as follows: 
95°C 30  s, 25 cycles of 95°C for 30  s, 55°C for 1  min, and 
68°C for 1 min, followed by one cycle of 72°C for 5 min. The 
product was purified and restriction digested with XhoI and 
HindIII. The pmaxCloning™ vector was also digested with 
XhoI and HindIII and dephosphorylated with Antarctic AP 
(New England Biolabs). Products were purified and ligated 
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with T4 DNA ligase (New England Biolabs). DH5α-TIR E. coli 
(ThermoFisher Scientific) were transformed and subject to 
kanamycin resistance selection. Resistant colonies were picked 
and screened via colony PCR using the same primers and cycling 
conditions of: 95°C for 10 min, 30 cycles of 95°C for 20 s, 56°C 
for 30 s, 72°C for 1 min, and one cycle of 72°C for 5 min. The 
PCR mix consisted of the same reagents at the same concentra-
tions as indicated in Section “Genotyping.” PCR products were 
visualized on a 1% agarose gel with SYBR Safe DNA Gel Stain 
(ThermoFisher Scientific). A positive colony was further grown 
in E. coli and plasmid was isolated using the ZymoPURE™ 
Plasmid Maxiprep Kit (Zymo Research). Confirmation of 
plasmid sequence was done at Genewiz (South Plainfield, NJ, 
USA) with the forward and reverse primers. For the cloning 
of IRF5, a PCR was also done on the donor fusion protein 
plasmid to introduce EcoRI and XhoI sites for more straight-
forward cloning. The primers used were as follows: forward 5′ 
TATAGAATTCCCAAG-CTGGCTAGTTAAG 3′, reverse 5′ 
TATACTCGAGATCGAACCACTTTGTACAAGAAA 3′. The 
PCR consisted of 150 ng plasmid DNA, PrimeSTAR® HS DNA 
Polymerase with reaction buffer (Takara), 0.25  µM primers, 
0.2 mM dNTPS (Takara), and sterile PCR-grade H2O. Cycling 
conditions were 30 cycles of 98°C for 10 s, 55°C for 15 s, and 72°C 
for 1 min. The product was purified and restriction digested with 
XhoI and EcoRI. The pmaxCloning™ vector was also digested 
with XhoI and EcoRI. Recipient vector dephosphorylation, 
ligation, and transformation, and colony PCR procedures were 
the same as done for CFP, but colony PCR primers were as fol-
lows: forward 5′ CCTGTGTCAGTGCAAGGTGT 3′, reverse 5′ 
TTCCCCAAAGCAGA-AGAAGA 3′. Products were also visu-
alized on a 1% agarose gel. A positive colony was grown up and 
plasmid DNA isolated the same way as for CFP. Confirmation 
of plasmid sequence was done at GENEWIZ (South Plainfield, 
NJ, USA) with the forward and reverse primers.
generation of luciferase reporter 
constructs
We obtained another plasmid with the non-risk IRF5 promoter 
(NM_002200) from Genecopoeia (HPRM19470-PG02). To 
obtain the promoter with the risk allele, a PCR was performed on 
donor genomic DNA with restriction sites for EcoRI and HindIII 
in the product. The primers used were as follows: forward 5′ 
TCTTGGAATTCCCCTCCTGTTTTCCTTCCCTGCTAT 3′, 
reverse 5′ GCCA-ACCTGCCGGGCACT 3′. The reaction used 
20  ng DNA and the same reagents and concentrations as the 
PCR described in Section “Genotyping,” but final concentrations 
of DMSO, MgCl2, and primers were 3.5%, 1.5 mM, and 0.5 µM, 
respectively. The cycling conditions were 95°C for 5 min, 38 cycles 
of 95°C for 20 s, 63°C for 30 s, 72°C for 1 min, and 1 cycle of 72°C 
for 5 min. Both the donor plasmid and PCR product were restric-
tion digested with EcoRI and HindIII; the donor plasmid was 
then dephosphorylated, ligated with the product, transformed 
into E. coli, grown and isolated the same way as described in 
“Generation of IRF5 and CPF-overexpressing constructs.” At 
this point we had two plasmids; one with the non-risk allele and 
one with the risk allele. We also obtained pGL4.10 promoterless 
Firefly and pRL thymidine kinase (TK) promoter-driven Renilla 
luciferase vectors (Promega). We digested the promoterless firefly 
vector, the non-risk allele plasmid, and the risk allele plasmid 
with BglII and HindIII (New England Biolabs), dephosphoryl-
ated the donor Firefly vector, and ligated it with either the purified 
non-risk or risk allele insert. Ligation products were transformed 
into E. coli and selected based on carbenicillin resistance. 
Colonies were picked and screened via colony PCR using the 
same primers as in Section “Genotyping.” The colony PCR was 
done with the same reagents and concentrations as in Section 
“Genotyping,” but cycling conditions were as follows: 95°C for 
10 min, 40 cycles of 95°C for 20 s, 56°C for 30 s, 72°C for 1 min, 
and 1 cycle of 72°C for 5 min. Products were visualized on a 1% 
agarose gel. A successful colony was transformed into E. coli, 
grown and isolated the same way as described in “Generation of 
IRF5 and CPF-overexpressing constructs.” The resulting non-risk 
allele Firefly vector and risk allele Firefly vector were confirmed 
by sequencing at GENEWIZ with the forward primer used in 
Section “Genotyping.” Mutation of the risk allele in the Firefly 
vector to a non-SP1 binding site was done with the QuikChange 
II Site-Directed Mutagensis Kit according to manufacturer’s 
instructions. The mutagenic primers used were as follows: for-
ward 5′ GGGCGGGGCGGTTCCGGGCAC-TGCCC 3′, reverse 
5′ GGGCAGTGCCCGGAACCGCCCCGCCC 3′.
Transient Transfection and irF5 
Overexpression
Raji and Daudi cells were transfected with 4  µg plasmid DNA 
using the Amaxa Nucleofector Kit V and 3  µg DNA using the 
Amaxa Nucleofector™ Kit L (Lonza), respectively, according to 
the manufacturer’s instructions. Half the amount of DNA in each 
cotransfection reaction consisted of the CFP reporter vector, and 
the resultant amount consisted of either IRF5 overexpression 
vector or empty vector. To control for plasmid size, IRF5 over-
expression vector or empty vector were transfected in equimolar 
amounts. Transfected cells were incubated in culture medium for 
24 h at 37°C in a humidified 5% CO2 incubator. For experiments 
involving stimulation of transfected cells with IRF5 activating 
agents, cells were placed into culture medium with 2.5 µM CpG 
or 5 µg/ml R848 immediately after transfection.
luciferase reporter gene assay
The following table illustrates transfection conditions for the 
given cell lines:
cell line μg Dna nucleofector™ cell 





Ramos 4 V, O-06 10:1 16
Raji 4 V, M-13 10:1 16
Daudi 3 L, A-20 10:1 16
Jurkat 2 V, X-01 10:1 16
THP-1 2 V, V-01 2:1 13
Transfected cells were incubated in culture medium for 24 h at 
37°C in a humidified 5% CO2 incubator. After incubation, firefly 
and renilla activity was measured using the Dual-Glo® Luciferase 
Assay System (Promega) according to the manufacturer’s 
instructions. Four independent experiments were done with all 
FigUre 1 | Common interferon regulatory factor 5 (IRF5) risk and non-risk haplotypes are present across various populations. (a) Chromosomal location of the 
IRF5 locus of interest with SNPs considered in our study. Alleles are indicated as non-risk:risk. (B) Condensed haplotypes obtained from 1000 Genomes present  
in >5% of the indicated ethnic populations. Those labeled risk and non-risk were included in our study. Abbreviations: ins, insertion; del, deletion.
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five cell lines comparing the risk and non-risk promoters; three 
independent experiments were done with THP-1 cells comparing 
the risk, non-risk, and mutated promoters.
electro-Mobility shift and supershift 
assays
Ramos, Raji, Daudi, and THP-1 cells were subcultured at 4 × 105/
ml and harvested when a total of 35 × 106 cells was present (~48 h 
later). Nuclear extract was prepared using the NE-PER® Nuclear 
and Cytoplasmic Extraction Kit (ThermoFisher Scientific) 
according to the manufacturer’s instructions. Infrared (700  nm) 
labeled oligonucleotides were obtained from Integrated DNA 
Technologies (Coralville, IA, USA). Probe sequences used were 
as follows: non-risk 5′ AGTGGATTCGCGGGG-CGGGGCGGG 
GCACTGC 3′, risk 5′ AGTGGATTCGCGGGGCGGGGCGGGGC 
GGGGCACT-GC 3′. The Odyssey Infrared electro-mobility shift 
assay (EMSA) Kit (LI-COR) was used according to the manufac-
turer’s instructions. For supershift reactions, 1 µg rabbit anti-SP1 
or isotype control (Cell Signaling Technology) was used. Gels were 
imaged on a LI-COR Infrared Odyssey machine.
statistical analysis
Statistical analyses were performed with GraphPad Prism 6 
software. Statistical significance was determined with the follow-
ing tests where indicated: Friedman test with Dunn’s multiple 
comparison test, Wilcoxon matched-pairs signed rank test, 
Mann–Whitney test, and the Kruskal–Wallis test. p Values < 0.05 
were considered significant.
resUlTs
common irF5 risk and non-risk 
haplotypes are Present across Various 
Populations
Using the 1000 Genomes Project data (36), we determined haplo-
type frequencies for the IRF5 locus (Figure 1A) for AFRs, Latino/
Hispanics, EASs, EURs, and SASs Most of the IRF5 variants associ-
ated with SLE are in a high degree of LD (Figure 1B). In all popula-
tions, the risk variants of rs142738614, rs2004640, rs10954213, and 
rs10488631 are inherited together, with the exception of the risk 
allele of rs10488631 which is present at a frequency <5% in AFRs 
and EASs. Our data show that (1)  rs142738614, rs2004640, and 
rs10954213 are three suitable markers for determining the presence 
of the common risk and non-risk haplotype across populations 
and (2) four copies of the CGGGG sequence of the rs142738614 
promoter indel is a suitable proxy for the risk haplotype.
irF5 expression is higher in Monocytes 
and igD− Memory B cell subsets 
independent of haplotype
In SLE, B cell tolerance checkpoints are compromised (37), and 
it has been shown that SLE risk alleles can affect those tolerance 
checkpoints. To address whether the IRF5 risk haplotype might 
affect B  cell tolerance, we first asked whether IRF5 expression 
differs across B cell subsets and whether the risk and non-risk 
haplotypes are differentially regulated as expression quantitative 
FigUre 2 | Interferon regulatory factor 5 (IRF5) expression is higher in monocytes and IgD− memory B cell subsets independent of haplotype. Monocytes and four 
subsets of B cells were sorted after gating on CD14+ and CD19+ cells, respectively. (a) Gating strategy for IgD+CD27+, IgD−CD27+, CD27−CD10loCD38l0 (naive), 
and CD27−CD10hiCD38hi (transitional) B cells. Sorted cells were subjected to qPCR for IRF5 (B,c), and results are shown combined (B) and separated by haplotype 
(c). p < 0.01 by Friedman test with Dunn’s multiple comparisons test (B), p = ns by Mann–Whitney test for each B cell subset (c).
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trait loci (eQTL). We compared expression of IRF5 in B  cells 
alongside expression of IRF5 in monocytes. We sorted mono-
cytes based on expression of CD14 and gated B  cells based 
on CD19 expression. CD19+ B  cells were sorted into four 
populations: naïve (IgD+CD27−CD10loCD38lo), transitional 
(IgD+CD27−CD10hiCD38hi), and CD27+ memory B  cells, both 
IgD+CD27+ and IgD−CD27+ (Figure 2A). IRF5 expression was 
significantly higher in monocytes than in B cells, and highest in 
CD27+IgD− B cells out of all the sorted B cell subsets (Figure 2B). 
Whether or not B cells or monocytes were from subjects carry-
ing the risk or non-risk haplotype did not affect gene expression 
(Figure 2C). Thus, although IRF5 may play an important role in 
class switched, antigen-experienced B cells, the presence of the 
IRF5 risk haplotype does not alter gene expression in unstimu-
lated, circulating B cells or unstimulated monocytes.
irF5 risk alleles Do not Differentially 
affect irF5 expression by In Vitro 
stimulated B cells
The impact of some disease-associated risk haplotypes is seen 
only in activated cells as “response eQTLs.” We therefore asked 
whether stimulation of B  cells through an IRF-dependent 
pathway would trigger haplotype-specific expression differences. 
B cells were stimulated with the TLR9 and TLR7 agonists, CpG 
or R848, respectively, for 5 or 24  h and IRF5 gene expression 
was measured. Successful B  cell stimulation was confirmed by 
increased CD86 expression after 5 h (Figure 3A). We observed 
a slight but significant increase in IRF5 expression 5 h after CpG 
stimulation as well as a decrease in expression 24  h after CpG 
or R848 stimulation (Figure 3B) confirming that IRF5 is within 
the TLR7 and 9 pathways. The presence of the IRF5 risk or non-
risk haplotype did not differentially affect the response to TLR 
agonists (Figure 3C).
susceptibility to apoptosis in B cells Does 
not Differ according to irF5 haplotype
While we observed no significant difference in basal or stimu-
lated levels of expression of IRF5, we thought it important to ask 
whether an effect of the IRF5 risk haplotype might be revealed in 
a more sensitive bioassay. IRF5 is known to play a critical role in 
cell cycle arrest and cell death (7). Irinotecan (CPT-11), a potent 
topoisomerase inhibitor and DNA damaging agent, activates an 
FigUre 3 | Interferon regulatory factor 5 (IRF5) risk alleles do not affect induced IRF5 expression in B cells. Purified B cells were stimulated with toll-like receptor 
agonists CpG or R848 for the indicated times and subjected to qPCR for CD86 (a) or IRF5 (B,c) IRF5 qPCR. Results are shown combined (B) and separated by 
haplotype (c). Unstimulated cell expression values are normalized to 1.0. p < 0.05, p < 0.01, and p < 0.0001 by Friedman test with Dunn’s multiple comparisons 
test (a,B), p = ns by Wilcoxon matched-pairs signed rank test for each treatment (c).
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IRF5-dependent apoptotic program (38). We asked whether IRF5 
haplotypes differentially affect apoptosis induced by CPT-11. 
PBMCs from healthy genotyped donors were treated with 50 µM 
CPT-11 or vehicle for 8 h and analyzed for the expression of active 
caspase 3 by flow cytometry. CPT-11 induced a significant increase 
in caspase 3 positive PBMCs (Figure 4A). The effect of CPT-11 on 
inducing active caspase 3 was evident in both B cells (CD19+) and 
monocytes (CD14+) (Figures 4C,D, top). Interestingly, there was 
a haplotype dependent induction of apoptosis in monocytes; risk 
haplotype carriers had a higher proportion of cells undergoing 
apoptosis than non-risk haplotype carriers (Figures 4B,D, bot-
tom). This haplotype dependent induction of apoptosis was not 
evident in B cells (Figures 4B,C, bottom). These findings suggest 
that although IRF5 plays a role in apoptosis in multiple cell types, 
the SLE risk haplotype enhances IRF5-mediated apoptosis in 
monocytes and not in B cells.
irF-specific B cell stimulation results in 
Upregulated cD86 expression and asc 
Differentiation
Based on murine studies, IRF5 has been shown to play a role in 
heavy chain class switch recombination to IgG (17, 18) and in 
plasma cell differentiation which requires upregulation of the 
transcription factor Blimp1 (15); IRF5 controls Blimp1 expression. 
We were interested in determining whether IRF5 haplotypes dif-
ferentially promote class switching and plasma cell differentiation 
in human B  cells. Naïve B  cells were cultured with or without 
CpG for 4  days and subjected to multiple functional assays 
including ELISpot, ELISA, and flow cytometry. B cell activation 
was demonstrated by upregulation of CD86 (Figures 5A,B, left), 
but the degree of upregulation did not differ according to hap-
lotype (Figure 5B, right). ELISpot analysis indicated that CpG 
induced B  cells to differentiate into IgM ASCs (Figure  5C, far 
left). We confirmed IgM secretion by ELISA (Figure 5C, center 
right). CpG treated cells also exhibited increased surface IgM 
(Figure 5D, left and center). In all these analyses, results did not 
differ according to IRF5 haplotype (Figure 5C, center left and far 
right; Figure 5D, right).
IgG secreting cells or surface IgG+ cells were not detected after 
the 4-day culture (data not shown), suggesting CpG alone may 
not be sufficient to induce class switching to IgG or that 4-day 
cultures are too short term for production of IgG to be evident. 
We therefore decided to perform quantitative PCR to measure 
the relative abundance of IgG germline mRNA in naïve B cells 
cultured with or without CpG for 24 h. Transcription of germline 
constant region mRNA is reported to precede isotype switching 
(39); the resulting transcripts are not translated into protein and 
are therefore termed “sterile transcripts.” We considered that 
we might detect these sterile transcripts before we could detect 
FigUre 4 | Susceptibility to apoptosis in B cells does not differ according to interferon regulatory factor 5 haplotype. Fresh peripheral blood mononuclear cells 
(PBMCs) were treated with 50 mM CPT-11 for 8 h, stained for CD19, CD14, viability dye, active caspase 3, and analyzed by flow cytometry. (a) Representative  
dot plots of vehicle and CPT-11-treated PBMCs. (B) Representative dot plots showing proportions of caspase 3+ B cells (top row) and monocytes (bottom row) 
in risk (left column) and non-risk (right column) haplotype subjects. (c) Proportion of apoptotic CD19+ cells shown combined (top) and separated by haplotype 
(bottom). (D) Apoptotic CD14+ monocytes shown combined (top) and separated by haplotype (bottom). p < 0.0001 by Wilcoxon matched-pairs signed rank test 
[(c,D), top], p = ns by Mann–Whitney test for each treatment [(c), bottom], p < 0.05 by Mann–Whitney test for each treatment [(D), bottom].
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IgG proteins. Surprisingly, we observed a decrease in abundance 
of sterile transcripts (Figure 6) and this decrease was observed 
equally in risk and non-risk haplotype B  cells, suggesting that 
TLR7 and 9 signaling may not be sufficient for class switch recom-
bination. Overall, we found that CpG stimulation upregulates 
CD86 and surface IgM on B cells and transforms naïve B cells 
into IgM secreting cells, and these effects occur independent of 
IRF5 haplotype.
irF5 Does not affect Fcγriib expression 
in B cells
The expression of FcγRIIb on B  cells represents an important 
B  cell tolerance mechanism. Triggering FcγRIIb serves as one 
mechanism to limit B cell activation through delivery of inhibi-
tory signals that contribute to regulation of the immune response 
(22). SLE patients fail to upregulate FcγRIIb on CD27+ memory 
B cells (40). Studies with mouse models suggest the existence of 
FigUre 5 | B cell stimulation results in upregulated CD86 expression and antibody-secreting cell (ASC) differentiation. Naive B cells were cultured for 4 days with or 
without CpG and analyzed by flow cytometry. (a) Representative histogram of CD86 expression on untreated (shaded peak) and CpG-treated (black outlined peak) 
B cells. (B) CD86 expression on B cells combined (left) and separated by haplotype (right). (c) ELISpot data showing proportion of ASCs combined (far left) and 
separated by haplotype (center left) and ELISA data showing IgM secretion by B cells combined (center right) and separated by haplotype (far right).  
(D) Representative histogram of surface IgM expressed on untreated (shaded peak) and CpG-treated (black outlined peak) B cells. Flow cytometric results of IgM 
expression on B cells combined (center) and separated by haplotype (right). p < 0.001 by Wilcoxon matched-pairs signed rank test [(B), left; (c), far left and center 
right; (D), center], p = ns by Mann–Whitney test for each treatment [(B), right; (c), center left and far right; (D), right].
FigUre 6 | Expression of sterile transcripts in B cells. B cells were cultured for 24 h with or without CpG and subject to qPCR for germline IgG. Results are shown 
combined (left) and separated by haplotype (right). p < 0.001 (left) by Wilcoxon matched-pairs signed rank test, p = ns by Mann–Whitney test (right).
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FigUre 7 | Interferon regulatory factor 5 risk alleles do no affect baseline FcγRIIb expression in B cell subsets. B cell subsets were analyzed similarly as in Figure 1. 
(a) Flow cytometric results of FcγRIIb protein expression in combined B cell subsets and (B) separated by haplotype. p < 0.05 and p < 0.0001 by Friedman test 
with Dunn’s multiple comparisons test (a), p = ns by Mann–Whitney test for each B cell subset (B).
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crosstalk between FcγRIIb and IRF5 with negative regulation of 
FcγRllb by IRF5 (20). We asked whether a relationship between 
IRF5 and FcγRIIb exists in human B cells, and if the IRF5 risk 
haplotype might be associated with a decrease in FcγRllb expres-
sion. Expression of FcγRIIb was measured on B  cell subsets 
from genotyped subjects using flow cytometry. Overall, FcγRIIb 
expression was highest on IgD+CD27+ B cells (Figure 7A). IRF5 
haplotype did not differentially affect FcγRIIb expression in any 
B cell subset (Figure 7B). These results show that the IRF5 risk 
haplotype does not affect expression of FcγRIIb on B cells.
We next asked whether IRF-dependent stimulation of B cells 
would result in haplotype-specific differences in FcγRIIb expres-
sion. B cells were stimulated with CpG or R848 for up to 40 h, and 
FcγRIIb transcript and protein expression were measured by qPCR 
and flow cytometry, respectively. CpG and R848 stimulation both 
resulted in significant decreases in FcγRIIb mRNA expression as 
early as 5 h after stimulation (Figure 8A). Surprisingly, protein 
expression remained unaffected and increased slightly at 24 and 
40 h after R848 stimulation (Figure 8C). Although statistically 
significant, the changes in protein we observed in R848 stimu-
lated B cells were very small and it is uncertain whether changes 
of this magnitude are enough to affect the biology of B cells. There 
were no haplotype-specific effects on mRNA or protein levels 
(Figures 8B,D). Considering IRF5 expression is low in B cells, we 
next sought to determine whether overexpressing IRF5 in B cells 
would have a measureable effect on expression of FcγRIIb. We 
hypothesized that overexpressing IRF5 would result in a decrease 
in FcγRIIb, similar to the negative regulation seen in mice (20). 
First we assessed expression of FcγRIIb in the Ramos, Raji, and 
Daudi human B cell lines (Figure 9A). We chose to utilize Raji 
and Daudi cells, as both expressed significant levels of FcγRllb. 
We cotransfected Raji and Daudi cells with a CFP reporter plas-
mid and either an IRF5 or empty (mock) plasmid. We isolated 
CFP+ cells (Figure 9B, center left) and analyzed IRF5 transcript 
(Figure 9C, top center left and far left) and protein (Figure 9B, 
center right and Figure 9C, top center right and far right) and 
FcγRIIb transcript (Figure 9C, bottom center left and far left) and 
protein (Figure 9B, far right and Figure 9C, bottom center right 
and far right) levels. We confirmed an increase in IRF5 mRNA 
and protein, but expression of FcγRIIb RNA and protein was 
unchanged.
To determine whether stimulation of the transfected cells 
was necessary to activate the overexpressed IRF5, transfected 
cells were stimulated with CpG or R848 for 24 h and analyzed by 
flow cytometry. Activation of overexpressed IRF5 did not affect 
FcγRIIb expression (Figure 9D). These findings show that over-
expressing or activating IRF5 does not affect FcγRIIb expression 
in human B cells.
The irF5 Promoter risk indel results 
in increased sP1 Binding and irF5 
Transcription in Myeloid cells
We decided to assess the strength of the IRF5 promoter contain-
ing either three or four repeats of the 5 bp CGGGG sequence in 
various cell lines: myeloid, T cell, and B cell lines. Previous work 
has shown increased IRF5 expression with the risk indel in ex vivo 
PBMCs and in HEK293 cells using a minigene assay (32). We cre-
ated two Firefly luciferase reporter plasmids; one with the three 
repeats of CGGGG and one with four repeats, and used a normal-
izing Renilla luciferase plasmid under control of the constitutive 
HSV-TK promoter. Ramos, Raji, Daudi, Jurkat, and THP-1 cells 
were transfected and analyzed for relative luciferase light units 
(Figure 10A, left). The basal level of IRF5 transcription is highest 
in THP-1 cells. The fold change in IRF5 transcription was also 
highest in THP-1 cells, as was induction of IRF5 transcription 
(Figure 10A, center).
Four repeats of the 5 bp CGGGG sequence in the risk haplo-
type introduce another binding site for the transcription factor 
SP1 (32). We asked whether SP1 binding to this additional site 
has a role in increased transcription of IRF5. To this end, we 
created an additional 4× indel IRF5 promoter-Firefly luciferase 
plasmid, with one SP1 binding site mutated to a non-SP1 binding 
site. We transfected THP-1 cells with the mutated plasmid and 
FigUre 8 | Continued
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compared the results to the 3× and 4× indel promoter reporter 
plasmids. We hypothesized that if SP1 were important for the 
observed increased IRF5 transcription seen with the 4× indel, 
abolishing the additional binding site would result in luciferase 
readings similar to those obtained with the 3× promoter reporter 
plasmid. Interestingly, this result was obtained in THP-1 cells 
(Figure 10A, right). Thus, the SP1 transcription factor has a role 
in the increased transcription of the IRF5 risk haplotype observed 
in myeloid cells.
We next decided to assess binding of nuclear transcription 
factors from B cell lines and THP-1 cells to the 3× and 4× indel. 
Cell lysates were incubated with infrared-labeled oligonucleo-
tides containing three or four repeats of CGGGG and analyzed 
by EMSA. A specific band was observed when the 4× indel was 
incubated with THP-1 nuclear extracts compared with extracts of 
the B cell lines (Figure 10B, left). The banding pattern was also 
present in Raji extract with the 4× indel, albeit very faintly. To ask 
whether the binding pattern observed in THP-1 cells was due to 
FigUre 8 | Interferon regulatory factor 5 activation does not affect FcγRIIb expression in B cells. (a,B) FcγRIIb mRNA expression in B cells treated with CpG (right) 
or R848 (left) for the indicated times. Results are combined (a) and separated by haplotype (B). (c,D) FcγRIIb protein expression in B cells treated with CpG (right) 
or R848 (left) for the indicated time. Results are combined (c) and separated by haplotype (D). All unstimulated cell expression values are normalized to 1.0. p < 0.05, 
p < 0.01, p < 0.001, and p < 0.0001 by Friedman test with Dunn’s multiple comparisons test (a,c), p = ns by Mann–Whitney test for each treatment (B,D).
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SP1, we performed a supershift EMSA with anti-SP1 antibody. 
Interestingly, we observed a change in the pattern when cell 
lysates were incubated with anti-SP1 (Figure 10B, right). We then 
asked if this is due to higher IRF5 and SP1 expression in THP-1 
cells compared with B cell lines. We observed that both IRF5 and 
SP1 (Figure 10C) mRNA levels were higher in THP-1 cells than 
in B cell lines. The data suggest that the differential expression of 
SP1 in monocytes and B cells is responsible for the haplotype-
specific increased expression of IRF5 observed in myeloid cells 
and not in B cells.
FigUre 9 | Interferon regulatory factor 5 (IRF5) overexpression does not affect FcγRIIb expression in Raji and Daudi cells. (a) FcγRIIb expression in Ramos, Raji, 
and Daudi cells. (B) Representative flow cytometric data showing untransfected (far left) and transfected (center left) cells. Gated cells were used for sorting and 
analyses. Representative histogram of IRF5 protein expression on mock (red) and IRF5 (blue) transfected cells (center right), representative histogram of FcγRIIb 
protein expression on mock (red) and IRF5 (blue) transfected cells (far right). (c) IRF5 mRNA (top row, far left and left) and protein (top row, far right and right) levels 
in CFP+ cells. FcγRIIb mRNA (bottom row, far left and left) and protein (bottom row, far right and right) levels in CFP+ cells. (D) FcγRIIb protein levels in CFP+ cells 
stimulated with CpG or R848 for 24 h. All data shown are representative of three independent experiments.
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DiscUssiOn
Approximately 100 genes have been identified in GWAS of SLE 
(41); however, the functionality of the majority of the risk alleles 
has not been elucidated. The goal of this study was to define an 
SLE-associated IRF5 risk haplotype and determine the effects 
of the risk haplotype on the biology of B cells. We first defined 
a risk haplotype common to various populations that included 
the 4× CGGGG indel in the promoter region and two risk SNPs, 
rs10954213 and rs2004640. Our major findings were (1) the 
IRF5 risk haplotype does not affect quantitative IRF5 expression 
in resting or activated B cells, (2) IRF5 activation triggers CD86 
upregulation and differentiates B cells into IgM ASCs, but this 
is not influenced by IRF5 haplotype, (3) IRF5 does not regulate 
FcγRIIb in human B cells, (4) the IRF5 risk haplotype differentially 
affects IRF5-mediated apoptosis in monocytes and not in B cells, 
and (5) the transcription factor SP1 binds more strongly to the 
4× CGGGG indel in myeloid cells and not in B cells. Collectively, 
our findings suggest that genetic risk haplotypes need to be 
understood in the context of cell lineage-specific functionality. 
Thus, somewhat unexpectedly, in the case of B cells and based on 
our assays cell intrinsic effects of IRF5 haplotypes do not appear 
to be an important factor in risk for SLE. This, of course, does 
not rule out cell intrinsic effects that we have not studied and cell 
extrinsic effects of IRF5 haplotypes on B cell function, mediated 
perhaps through myeloid cell lineages (42).
We note that the literature provides some evidence that 
contrasts with our findings. In particular, the original definition 
of the IRF5 haplotypic diversity by Graham et  al. showed that 
SLE risk alleles regulate expression of IRF5 in B lymphoblastoid 
cell lines. This was most clearly demonstrated for the rs10954213 
allele that also regulates the formation of the short and long forms 
FigUre 10 | The interferon regulatory factor 5 (IRF5) promoter risk insertion/deletion (indel) results in increased IRF5 transcription and specificity protein 1 (SP1) 
binding in myeloid cells. (a) Normalized activities of non-risk and risk indel promoter-driven luciferase transcription in various cell lines (left), fold change in luciferase 
activity due to the risk indel in various cell lines (center), and risk, non-risk, and mutated promoter-driven luciferase transcription in THP-1 cells (right). Results of three 
or four independent experiments are shown. (B) Electrophoretic mobility shift assay showing binding to the 3× and 4× CGGGG indel by various nuclear extracts 
(left), supershift assay showing SP1 binding to the 3× and 4× CGGGG indel in nuclear extracts of THP-1 cells (right). Results of three independent experiments 
are shown. (c) SP1 mRNA levels in various cell lines. Results of three independent experiments are shown. p < 0.05 by Kruskal–Wallis test [(a), center].
15
Calise et al. Cell-Specific Risk Haplotype Effects
Frontiers in Immunology | www.frontiersin.org May 2018 | Volume 9 | Article 996
of the polyA tail of IRF5. Overall gene expression was assessed 
with Northern blot analysis or using microarray data in public 
databases, whereas our studies have utilized a TaqMan assay 
that is directed to the exon 2–3 boundary. Thus, it is possible 
that these two approaches may give different results in terms 
of overall quantitation of message due to differences in mRNA 
isoforms. Our approach to mRNA quantitation may have missed 
quantitative differences in the various mRNA splice variants that 
are encoded the risk and non-risk haplotypes. It is also possible 
that B  cell lines have regulatory mechanisms that differ from 
native B cell populations. Nevertheless, our data strongly suggest 
that if mRNA splicing differences do exist between the risk and 
non-risk haplotypes, they do not substantially affect the B  cell 
functional assays we have described here. Therefore, regardless of 
the mechanism, differences in haplotype transcriptional patterns 
do not appear to have a cell intrinsic effect on the critical B cell 
functions that we have investigated. It may well be that transcript 
isoforms do play some role in B cell functions that we have not 
examined, but our data address the major mechanisms that have 
been reported to be associated with B cell abnormalities in lupus.
These data emphasize the level of complexity that must be 
considered when trying to understand gene association studies 
with disease related phenotypes, namely that a gene may serve 
a critical purpose in a particular cell type, but a risk haplotype 
may or may not function differently from the non-risk haplotype 
in that cell type. The chain of causation in autoimmune diseases 
such as SLE clearly involves complex cell-cell interactions. The 
data reported here strongly suggest that the influence of IRF5 
on B cell abnormalities is likely to depend to a large degree on 
the effects of IRF5 on cells which have a regulatory role on B cell 
function, such as myeloid cells. Further functional studies of IRF5 
can profitably be focused on this possibility.
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